A large contemporary U.S. electronic health record analysis highlights elevated risks of severe maternal morbidity and preterm birth among pregnant individuals with sickle cell disease, offering updated...
On November 10, the U.S. Department of Health and Human Services announced that the FDA is initiating the removal of certain black box warnings from hormone replacement therapy products for menopause,...
A phase 2 nonrandomized clinical trial explored whether breast surgery could be safely eliminated for women with ERBB2-positive or triple-negative invasive breast cancer who achieved a pathologic complete...
A randomized trial in breast cancer survivors found that just one session of resistance or high-intensity interval training significantly elevated circulating anti-cancer myokines and reduced the growth of...
A new analysis of the Women’s Health Initiative trials found that menopausal hormone therapy effectively reduces vasomotor symptoms without increasing cardiovascular risk in women aged 50 to 59 years....
The phase 3 SERENA-6 trial evaluated whether replacing an aromatase inhibitor with camizestrant while continuing a CDK4/6 inhibitor in patients with ER-positive, HER2-negative advanced breast cancer and...
A recent study found that daily supplementation with myo-inositol during pregnancy did not reduce the risk of gestational diabetes, preeclampsia, or preterm birth in individuals with polycystic ovary...
In a multicenter trial of women with low-prognosis in vitro fertilization, investigators compared the effectiveness and safety of elective freeze-all versus fresh embryo transfer.
Recent findings presented at the American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting 2025 support several effective pain-reducing methods for outpatient...
The results from a randomized, placebo-controlled trial showed that oral probiotic supplementation did not reduce the recurrence of vulvovaginal infections in pregnant women following successful treatment....
